Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Saliva Diagnostics (SALV) -- Ignore unavailable to you. Want to Upgrade?

To: RSH who wrote (3204)	10/14/1999 11:03:00 PM
From: RSH	Respond to of 3369

Potential investors, take a look at (SALV)'s products. salv.com salv.com salv.com salv.com (SALV) has invested over $30 million in the last several years researching, developing, and manufacturing these products. They are currently being sold with foreign contracts yet need an FDA approval to be marketed in the US. Meridian Diagnostics is in a position to fast-track an FDA approval for these products. Meridian Diagnostics (KITS) needs these products in their inventory which is why they have apparently made an offer to purchase Saliva Diagnostics, Inc. (SALV). IMHO, there is minimal downside to purchase (SALV) for under $1.00/share with these excellent products. Ron

To: RSH who wrote (3204)	10/14/1999 11:04:00 PM
From: Shadow	Read Replies (1) \| Respond to of 3369

Ron, The slimy offshore (Cayman Island) deals are there for you to read in the last three year's SEC filings. All you have to do is read them. When you are reading the SEC filings pay particular attention to Tailwind Fund LTD (of the Cayman Islands). I've been following SALV for 3 years now. They have announced contracts and approvals in countries to numerous to mention. Most of these announcements were followed by Tailwind and friends dumping stock into the buying generated by the PR's. Strangely enough none of these contracts or approvals have produced any significant revenue that shows up on quarterly reports. Careful research will show an uncanny timing between fabulous PR's and the conversion dates for preferred share offerings. If SALV had sold all the tests their PR's said they have contracts for, the world would be awash in them. After three years of DD on SALV I believe I know what the problem is. IMO, these wonderful diagnostic tests cost more to produce than anyone is willing to pay. In closing, here is a portion of the last quarterly report. Please note, the most recent quarterly report has not been filed and is overdue. On January 22, 1999, the Company issued to The Tail Wind Fund Ltd. ("Tail Wind") 17,140 shares of its common stock, which Tail Wind was entitled to receive pursuant to the terms of a common stock purchase agreement dated as of June 30, 1997, pursuant to which Tail Wind had purchased 412,905 shares of the Company's common stock for an aggregate purchase price of $300,000. The subscription agreement provided for the issuance of such additional reset shares upon the occurrence of certain conditions related to the market price of the Company's common stock during a specified period. On March 2, 1999, the Company issued to Biscount Overseas Limited 1,364,516 shares of its common stock upon the conversion of 500 shares of the Company's Series 1998-B Convertible Preferred Stock. On March 25, 1999, the Company issued to Luc Hardy 1,500,000 shares of its common stock pursuant to a settlement agreement between Mr. Hardy and the Company. See Note 6 of Notes to Consolidated Financial Statements. The Company's capital requirements have been and will continue to be significant. The Company currently has an accumulated deficit due to its history of losses. The Company is dependent upon its effort to raise capital to finance its future operations, including the cost of manufacturing and marketing of its products, to conduct clinical trials and submissions for FDA approval of its products and to continue the design and development of its new products. Marketing, manufacturing and clinical testing may require capital resources substantially greater than the resources available to the Company. In April 1999, the Company received $200,000 from the sales of 212 shares of its Series 1998-B Convertible Preferred Stock. In the second fiscal quarter of 1999, the Company expects to receive $270,000 (net of issuance costs of $30,000) from the sale of 288 shares of its Series 1998-B Convertible Preferred Stock. The Company believes that its current cash position and these expected proceeds, combined with revenues and other cash receipts, will be insufficient to fund the Company's operations through 1999. Substantial additional financing will be required in 1999. There can be no assurance that the Company will be able to obtain the additional capital resources necessary to implement or continue its programs, or that such financing will be available on commercially reasonable terms or at all. The Company will continue to seek public or private placement of its equity securities and corporate partners to develop products. There can be no assurance that the Company will be able to sell its securities on commercially reasonable terms or to enter into agreements with corporate partners on favorable terms or at all. The Company's future capital needs will depend upon numerous factors, including the progress of the approval for sale of the Company's products in various countries, including the U.S., the extent and timing of the acceptance of the Company's products, the cost of marketing and manufacturing activities and the amount of revenues generated from operations, none of which can be predicted with certainty. The Company's significant operating losses and capital requirements raise substantial doubt about the Company's ability to continue as a going concern.